Pearce IP BioBlast: w/e 09 October 2020
Significant biosimilar activities this week include:
05 Oct 20: Medicure announced it has entered a License, Manufacture and Supply Agreement with Reliance Life Sciences for a cardiovascular biosimilar product for EU, US and Canada. Medicure is responsible for the regulatory approval process for that product.
06 Oct 20: Onco'Zine reported a new study released by the American Society of Clinical Oncology Quality Care Symposium indicates that Sandoz's Zarxio® (biosimilar filgrastim) is not only safe and effective, but is cost effective in treating chemotherapy-induced febrile neutropenia in early-stage breast cancer patients.
06 Oct 20, EU: Samsung Bioepis and Biogen announced the European Medicines Agency has accepted for review its Marketing Authorisation Application for SB11 (proposed ranibizumab biosimilar).
08 Oct 20: Korea Biomedical Review reported Celltrion has received approval for Ph III trials of CT-P39 (proposed omalizumab biosimilar).